No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong Stock Announcement Gold Mining | Bosideng (03998) announces mid-term performance, the profit attributable to equity shareholders rose by 23% year-on-year to approximately 1.13 billion yuan.
Dianzhi (02586) will conduct IPO from November 28th to December 3rd, planning to globally issue 25.774 million shares; Reshaping Energy (02570) will conduct IPO from November 28th to December 3rd, planning to globally issue approximately 4.8279 million shares.
Express News | New Indication of Olverembatinib Included Into China 2024 National Reimbursement Drug List
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Asia Sheng Pharmaceutical appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors.
Rockville, Maryland and Suzhou, china, November 25, 2024 /PR Newswire/ -- As a leading biomedical company dedicated to developing innovative drugs in areas such as oncology, Ascletis Pharma (6855.HK) announced today the appointment of Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors of the company, effective November 25, 2024. Dr. Yang Dajun, chairman and CEO of Ascletis Pharma, stated: "We warmly welcome Ms. Marina S. Bozilenko and
No Data
